000919.SZ
Jinling Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 5.92
−0.34%Sep 22, 2026, 08:12 UTC
Jinling Pharmaceutical's controlling subsidiary Chizhou Dongsheng Pharmaceutical received China NMPA approval to market arolol hydrochloride as an active pharmaceutical ingredient for domestic production and sale.
Source:Sep 21, 2026, 08:52 UTC
Nanjing Jinling Pharmaceutical's controlling subsidiary Nanjing Jingu Hospital Management Co. was converted from bankruptcy liquidation to bankruptcy reorganization by order of the Xuanwu District People's Court of Nanjing, effective September 20, 2026.
Source:Aug 28, 2026, 08:25 UTC
Jinling Pharmaceutical announced its first-half 2026 results: revenue of 1.584 billion yuan, down 1.04% year-on-year; net profit attributable to shareholders of 50.3825 million yuan, up 4.24% year-on-year.
Jul 31, 2026, 08:59 UTC
Jinling Pharmaceutical's Fuzhou Meifeng Pharmaceutical Factory received an acceptance notice from the National Medical Products Administration for its marketing authorization application for ferric carboxymaltose injection.
Source: